These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 27249993)

  • 1. Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.
    Schìtz A; Moser S; Marchart K; Haltmayer H; Gschwantler M
    Am J Gastroenterol; 2016 Jun; 111(6):903-5. PubMed ID: 27249993
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
    Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ
    Clin Infect Dis; 2016 Dec; 63(11):1405-1411. PubMed ID: 27553375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
    Sollima S; Antinori S; Torre A; Binda F; Giacomelli A; Milazzo L
    Int J STD AIDS; 2017 Jul; 28(8):838-840. PubMed ID: 28632109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV.
    Paniagua-García M; López-Hernández I; Fernández-Cuenca F; Ríos-Villegas MJ
    Enferm Infecc Microbiol Clin; 2017 Dec; 35(10):681-682. PubMed ID: 28366615
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
    Stern R; Hametner S; Ramona AZ; Moser S; Karpi A; Laferl H; Stauber RE; Zoller HM; Maieron A; Vogel W; Graziadei I; Gschwantler M; Kozbial K; Freissmuth C; Hofer H; Ferenci P
    Am J Gastroenterol; 2016 May; 111(5):744-5. PubMed ID: 27151123
    [No Abstract]   [Full Text] [Related]  

  • 6. Streptococcus salivarius spontaneous bacterial peritonitis in a HIV/HCV-co-infected patient treated with direct antiviral agents.
    Domínguez-Domínguez L; de Lagarde-Sebastián M; de Miguel-Campo B; Pulido F
    Enferm Infecc Microbiol Clin; 2017 Mar; 35(3):199. PubMed ID: 26993439
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
    Biliotti E; Palazzo D; Serani M; Silvestri AM; Volpicelli L; Esvan R; Franchi C; Spaziante M; Sorrentino F; Taliani G
    Ann Hematol; 2017 Jun; 96(6):1043-1045. PubMed ID: 28378040
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
    Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
    AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis C with direct acting antiviral agents in patients with haemophilia, end-stage liver disease and coinfected with HIV.
    Ackens R; Posthouwer D
    Haemophilia; 2016 May; 22(3):e223-5. PubMed ID: 26988201
    [No Abstract]   [Full Text] [Related]  

  • 10. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)].
    Vicente-Sánchez S; Menéndez Naranjo L
    Farm Hosp; 2017 Mar; 41(2):313-314. PubMed ID: 28236804
    [No Abstract]   [Full Text] [Related]  

  • 12. Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
    Nafisi S; Roy S; Gish R; Manch R; Kohli A
    Expert Rev Anti Infect Ther; 2016; 14(1):41-56. PubMed ID: 26654939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
    Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
    Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.
    Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
    Addiction; 2016 Feb; 111(2):311-9. PubMed ID: 26451534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
    Ingiliz P; Christensen S; Kimhofer T; Hueppe D; Lutz T; Schewe K; Busch H; Schmutz G; Wehmeyer MH; Boesecke C; Simon KG; Berger F; Rockstroh JK; Schulze zur Wiesch J; Baumgarten A; Mauss S
    Clin Infect Dis; 2016 Nov; 63(10):1320-1324. PubMed ID: 27535952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials.
    Messori A; Brunetto MR; De Luca A; Zignego AL
    Dig Liver Dis; 2015 Nov; 47(11):988-9. PubMed ID: 26205830
    [No Abstract]   [Full Text] [Related]  

  • 17. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
    Werner CR; Schwarz JM; Egetemeyr DP; Beck R; Malek NP; Lauer UM; Berg CP
    World J Gastroenterol; 2016 Sep; 22(35):8050-9. PubMed ID: 27672299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
    Pérez-Pitarch A; Guglieri-López B; Ferriols-Lisart R; Merino-Sanjuán M
    Int J Antimicrob Agents; 2016 Mar; 47(3):184-94. PubMed ID: 26915476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.